Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
150
datasets available to search
ShareScore release 0.9.0
Dataset results
150 results for “Disease burden”
Estimating malaria disease burden in the Asia-Pacific
<p>This repository hosts all the Supplementary Material for the publication: Maude RJ, Mercado CEG, Rowley J, Ekapirat N, Dondorp AM. (2019) Estimating malaria disease burden in the Asia-Pacific (under review)</p>
Epidemiology and Disease Burden of Neurocritical Disorders: A Cohort Study - Data Sharing
<p>Dataset of a Neurocritical Brazil cohort study whose summary is described below.</p> <p><strong>Abstract</strong></p> <p><strong>Objective:</strong> To describe a cohort of neurocritical patients and their differences based on primary neurological diagnoses and identify predictors of mortality and unfavorable outcome along with the disease burden of each neurological condition on intensive care unit (ICU) admission. <strong>Methods:</strong> Prospective cohort study including patients admitted to 36 ICUs in Brazil and followed up for 30 days. <strong>Results:</strong> Of 4245 patients admitted to the participating ICUs during the study period, 1194 (28.1%) were neurocritical patients and were included in the study. Neurocritical patients had a mean mortality rate 1.7 times higher than non-neurocritical patients admitted to the same ICUs (17.21% versus 10.1%, respectively). The most frequent primary neurological diagnoses on ICU admission were postoperative care of elective neurosurgery, traumatic brain injury, ischemic stroke, and encephalopathy. The estimated total disability-adjusted life-years (DALYs) were 4482.94 in the overall cohort, and the diagnosis with the highest DALYs was traumatic brain injury (1634.42). DALYs were significantly impacted by the patients’ primary neurological diagnosis, sex, age group, and number of secondary neurological injuries. <strong>Conclusion:</strong> We accurately described the epidemiology of neurocritical patients and estimated their overall and relative disease burden. The findings of this study are important to direct policies regarding education, prevention, and treatment of severe neurocritical diseases.</p> <p> </p>
Work-related burden of diseases and disorders
<p><span>The burden of the work-related diseases is a major global health challenge. This data provides the global, regional and country level estimates on the work-related burden of occupational diseases and accidents for the year 2019 in terms of deaths, disability adjusted life years (DALYs) and economic loss as a percentage of total gross domestic product (GDP). </span></p> <p><span>The data contains calculated estimates based on the employment figures, mortality rates, occupational injuries, accidents, self-reported occupational illnesses and injuries from electronic data sources of international organizations, institutions, and public websites. Risk ratios (RR) and population attributable fractions (PAF) for the risk factors outcome pairs were derived from literature. Estimated mortality and DALYs for a group of seven major diseases covering 120 risk-outcome pairs attributable to work are calculated at global, WHO regions and at country level. The details of the methodology of the data have been published already (<a href="https://www.sjweh.fi/article/4132"><span>https://www.sjweh.fi/article/4132</span></a>).</span></p> <p><span>In general, the method is based on the number of problems identified at work: injuries, illnesses, and disorders including fatal or no-fatal cases. This was implemented by calculating the deaths, Years of Life Lost (YLL), Years Lived with Disability (YLD) and their combination Disability Adjusted Life Years (DALY) based on primarily ILO numbers as adjusted by the Institute of Health Metrics and Evaluation (IHME) Global Burden of Disease and Injury (GBD) process outcomes. While there are existing estimates updated annually by the GBD process, latest for the year 2019, these do cover only a selected group of occupational risks. Therefore, the GBD 2019 outcomes would not be comparable to ILO Estimates and – if directly used – would end up in clear underestimates of the size of the problem. The differences between ILO and GBD2015 outcomes are reported elsewhere. </span></p> <div> <div> <p><span> </span></p> </div> </div>
Appendix of the manuscript: The burden of disease attributable to high body mass index in Belgium
<p>These datasets are part of the Appendix of the manuscript: <em>The burden of disease attributable to high body mass index in Belgium </em>from Gorasso et al.</p> <p>Appendix 3 includes the relative risks by age, sex and disease extracted from GBD 2019 used in the manuscript;</p> <p>Appendix 4 includes the results of the population attributable fractions of high body mass index by age, sex and disease derived in the manuscript.</p>
Data and source code for: ClinVar and HGMD genomic variant classification accuracy has improved over time, as measured by implied disease burden
Open the record for dataset details and reuse information.
Radiological Risk in the Global Burden of Disease
<p>The contribution of radioactivity to the overall burden of disease has rarely been put in context of overall pollution of our environment, even though it has got high public interest as stand-alone problem. Indeed, radioactive pollution is not even mentioned in World health statistics 2020. Is it less important for health than in public policies? There is no general accepted common frame of reference, which would allow comparing risks of none-radioactive and radioactive pollutants and sharing methods for risk management. Annually, the WHO compares the impact of chemotoxic risk with those of many other risk factors, using the global burden of diseases and the disability adjusted loss of life years (DALY), a concept that has only recently been applied to radioactive contamination by Japanese researchers. Despite some effort for risk comparison, there seems to be a silent agreement between the experts from IAEA, WHO, OECD-NEA, ICRP and many national bodies as well as antinuclear civil society groups, in the field of assessing the health impact of radiotoxicity to treat radioactivity apart. Maybe, one of the reasons is that on global level, the largest impact of radiation stems from natural radioactivity. Taking for example the public debate on potential risks from future radioactive waste disposal sites. Compared to the risk from natural radiation, the risk contribution to future generations from a radioactive waste disposal site is expected to be thousand to millon times lower. And this risk is not for the next 10000 yrs but only for the time very much beyond, close to the age of the homo sapiens. Expressed in DALY, the number of cancers cases formally attributable to a life long exposure situation by natural radiation of 1 mSv corresponds for example for the japaneze population to a reduction of life expectancy of about 1 to 1.5 month for man or woman. Hence, the impact of a radioactive waste disposal site on potential reduction of life expencency of future generations will be well below 1 day. Probably, life expectency is even increased by geological disposal, as it reduces the risk stemming from surface storage sites, which are difficult to be controlled over the time of many generations. The ICRP shall help understanding radiological risks in the overall context of other risks, the society is taking everyday.</p>
Costs of attributable burden disease to PM2.5 ambient air pollution exposure in Medellín, Colombia, 2010-2016
<pre>The repository includes the consolidated databases design to analyze the economic cost of local attributable burden disease to PM2.5 ambient air pollution in Medellín from 2010-2016.</pre>
A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD)
ClinicalTrials.gov study NCT03488030. IPD Sharing: YES. Countries: 1. Publications: 1.
Status of Disease Burden of Lower Urinary Tract Symptoms in Chinese Male Community
ClinicalTrials.gov study NCT06352736. IPD Sharing: NO. Countries: 1. Publications: 6.
A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk
ClinicalTrials.gov study NCT01995175. IPD Sharing: NO. Countries: 8. Publications: 3.
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
ClinicalTrials.gov study NCT05562583. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Dataset related to article "Intracerebral Injection of Extracellular Vesicles from Mesenchymal Stem Cells Exerts Reduced Aβ Plaque Burden in Early Stages of a Preclinical Model of Alzheimer's Disease."
<p>Bone marrow Mesenchymal Stem Cells (BM-MSCs), due to their strong protective and anti-inflammatory abilities, have been widely investigated in the context of several diseases for their possible therapeutic role, based on the release of a highly proactive secretome composed of soluble factors and Extracellular Vesicles (EVs). BM-MSC-EVs, in particular, convey many of the beneficial features of parental cells, including direct and indirect β-amyloid degrading-activities, immunoregulatory and neurotrophic abilities. Therefore, EVs represent an extremely attractive tool for therapeutic purposes in neurodegenerative diseases, including Alzheimer's disease (AD). We examined the therapeutic potential of BM-MSC-EVs injected intracerebrally into the neocortex of APPswe/PS1dE9 AD mice at 3 and 5 months of age, a time window in which the cognitive behavioral phenotype is not yet detectable or has just started to appear. We demonstrate that BM-MSC-EVs are effective at reducing the Aβ plaque burden and the amount of dystrophic neurites in both the cortex and hippocampus. The presence of Neprilysin on BM-MSC-EVs, opens the possibility of a direct β-amyloid degrading action. Our results indicate a potential role for BM-MSC-EVs already in the early stages of AD, suggesting the possibility of intervening before overt clinical manifestations.</p>
Data from: Acute febrile illness and influenza disease burden in a rural cohort dedicated to malaria in Senegal, 2012-2013
Background: African populations are considered to be particularly vulnerable to fever illnesses, including malaria, and acute respiratory disease, owing to limited resources and overcrowding. However, the overall burden of influenza in this context is poorly defined and incidence data for African countries are scarce. We therefore studied the fever syndrome incidence and more specifically influenza incidence in a cohort of inhabitants of Dielmo and Ndiop in Sokone district, Senegal. Methods: Daily febrile-illness data were prospectively obtained from January 2012 to December 2013 from the cohort of the villages of Dielmo and Ndiop, initially dedicated to the study of malaria. Nasopharyngeal swabs were collected from, and malaria diagnosis tests (thick blood smears) carried out on, every febrile individual during clinical visits; reverse transcriptase-polymerase chain reaction was used to identify influenza viruses in the samples. Binomial negative regression analysis was used to study the relationship between the monthly incidence rate and various covariates. Results: In Dielmo and Ndiop, the incidence of malaria has decreased, but fever syndromes remain frequent. Among the 1036 inhabitants included in the cohort, a total of 1,129 episodes of fever were reported. Influenza was present all year round with peaks in October-December 2012 and August 2013. The fever, ILI and influenza incidence density rates differed significantly between age groups. At both sites, the adjusted incidence relative risks for fever syndromes and ILI were significantly higher in the [6–24 months) than other age groups: 7.3 (95%CI: [5.7–9.3]) and 16.1 (95%CI: [11.1–23.3]) respectively. The adjusted incidence relative risk for influenza was significantly higher for the [0–6 months) than other age groups: 9.9 (95%CI: [2.9–33.6]). At both sites, incidence density rates were lowest among adults > = 50 years. Conclusions: In this rural setting in Senegal, influenza was most frequent among the youngest children. Preventive strategies targeting this population should be implemented.
Measuring the disease burden of seasonal influenza in Germany 2015 – 2020 using the incidence-based disability-adjusted life years (DALYs)
<p>Version 1.0.0 was created. Dataset includes all parameters and values used for all scenario-specific calculations, using the Burden of Communicable diseases in Europe (BCoDE) tool.</p>
Population-based Age-stratified Seroprevalence Investigation on SARS-CoV-2 Virus in Selected States of High and Low Burden of Disease in Nigeria
<p>Results of population-based age stratified seroepidemiological investigation in Nigeria</p>
Supplementary Data: Sensitivity of Air Pollution Exposure and Disease Burden to Emission Changes in China using Machine Learning Emulation.
<p>Temporary duplicate of:</p> <p>Conibear, L., Reddington, C. L., Silver, B. J., Chen, Y., Arnold, S. R., & Spracklen, D. V. (2022). <em>Supplementary Data: Sensitivity of Air Pollution Exposure and Disease Burden to Emission Changes in China using Machine Learning Emulation. University of Leeds. [Dataset]</em>. https://doi.org/doi.org/10.5518/1055</p>
Source data for manuscript "Polygenic burden of short tandem repeat expansions promote risk of Alzheimer's disease"
<p>Included are the source data and scripts used to make all plots for the mansucript "Polygenic burden of short tandem repeat expansions promote risk of Alzheimer's disease"</p>
The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa
ClinicalTrials.gov study NCT04556188. IPD Sharing: UNDECIDED. Countries: 2. Publications: 1.
BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population
ClinicalTrials.gov study NCT00738725. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Reducing Chronic Kidney Disease Burden in an Underserved Population
ClinicalTrials.gov study NCT03832166. IPD Sharing: YES. Countries: 1. Publications: 44.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.